Literature DB >> 32238410

Innate and Acquired Resistance to Anti-EGFR Therapy-Letter.

Janardan P Pandey1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32238410      PMCID： PMC7138345          DOI： 10.1158/1078-0432.CCR-19-3935

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  4 in total

1.  IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding.

Authors:  David Ternant; Christophe Arnoult; Martine Pugnière; Christine Dhommée; Daniel Drocourt; Eric Perouzel; Christophe Passot; Nadine Baroukh; Denis Mulleman; Gérard Tiraby; Hervé Watier; Gilles Paintaud; Valérie Gouilleux-Gruart
Journal:  J Immunol       Date:  2015-12-18       Impact factor: 5.422

Review 2.  Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies.

Authors:  Christine M Parseghian; Stefania Napolitano; Jonathan M Loree; Scott Kopetz
Journal:  Clin Cancer Res       Date:  2019-07-01       Impact factor: 12.531

3.  ANTIBODY TO HEREDITARY HUMAN GAMMA-GLOBULIN (GM) FACTOR RESULTING FROM MATERNAL-FETAL INCOMPATIBILITY.

Authors:  H H FUDENBERG; B R FUDENBERG
Journal:  Science       Date:  1964-07-10       Impact factor: 47.728

4.  Mechanism of resistance to cetuximab therapy in colorectal cancer: Possible role of antibodies to immunoglobulin allotypes.

Authors:  Janardan P Pandey
Journal:  MAbs       Date:  2012-07-23       Impact factor: 5.857
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.